IL-33, Endocan and Endothelial Cells

Withdrawn

• Conditions: Endothelial Cell

• Registration Number: NCT03984383
• Lead Sponsor: University Hospital, Lille

Brief Summary

The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants.

For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells.

Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery.

Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-27
• Study First Submitted QC: 2019-06-11
• Study First Posted: 2019-06-13
• Study Start: 2021-11-08
• Primary Completion: 2021-11-08
• Study Completion: 2021-11-08
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-03
• Last Update Posted: 2022-11-04

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Age > 18 years
• signed consent
• Pregnant woman for umbilical cord-derive-endothelial cells

Exclusion Criteria

• Age < 18 years

• Refusal to participate to the study

• Endothelial cord-drived endothelial cells :

  • significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.)
  • infection for HIV, VHB, VHC
  • unknown status for HIV, VHB, VHC the day of the childbirth.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 48 hours after stimulation

Secondary Outcome Measures

Name	Time	Method
change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours after stimulation
change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation

Trial Locations

Locations (1)

Hop Calmette Chu Lille; 🇫🇷 Lille, France